Pamplona, Spain, 02 June 2016 – Cinfa Biotech S.L., the biosimilars company of Infarco group, today announced its participation at the following conferences:
Bio International Convention 2016
Date: 6 - 9 June 2016
Venue: Moscone Center, San Francisco, CA, USA
The Cinfa Biotech Team will be attending for partnering discussions. http://convention.bio.org
22nd EGA Annual Conference & 19th Annual IGPA Conference Date: 9 June 2016, 2:15 pm CEST (1:15 pm BST)
Venue: Radisson Blu Dubrovnik Hotel, Dubrovnik, Croatia
Dr Ruediger Jankowsky, Managing Director of Cinfa Biotech GmbH, will participate in the panel discussion on “Making Generic and Biosimilar Manufacturing Thrive: a Global Policy”.
http://www.egaevents.org/ega16/EGA16_Programme.pdf
Satellite symposium at EULAR Conference 2016
Date: 10 June 2016, 9:15 – 10:45 am CEST (8:15 - 9:45 am BST)
Venue: ExCel London, London, UK
Cinfa Biotech is a sponsor of the satellite symposium “Biosimilar Medicines for Rheumatologists: Understanding the Science of Extrapolation” which is organized by the Biosimilar Medicines Group.
http://www.congress.eular.org/myUploadData/files/EULAR%202016%20Satellite%20Symposia.pdf
5th European Biosimilars Congress
Date: 28 June 2016, 2:00 pm CEST (1:00 pm BST)
Venue: Meliá Valencia, Valencia, Spain
Dr Ruediger Jankowsky, Managing Director of Cinfa Biotech GmbH, will hold a plenary talk on “Overcoming the Challenges of Biosimilar Development as a Mid-size Player”.
http://biosimilars-biologics.pharmaceuticalconferences.com/europe/scientific-program.php?day=2&sid=1729&date=2016-06-28
About Cinfa Biotech
Cinfa Biotech is headquartered in Pamplona, Spain, with offices in Munich, Germany. Founded in 2013 and supported by its parent company Infarco, the Company is creating a pipeline of biosimilar drugs for a range of indications to address the growing need for affordable therapies based on proven science, quality, safety and efficacy. A complete team of experts with decades of in-depth experience is conducting product development, clinical studies, manufacturing and quality control, according to the highest European standards. Cinfa Biotech’s first product candidate in clinical development is B12019, a biosimilar version of Neulasta® (pegfilgrastim). The commercialisation models will be customised to the needs of partners and markets.
With 50 years’ experience, Infarco today employs over 1,200 people and reinvests an average of 90% of its annual profits in its portfolio companies, thereby driving their development and innovation. Infarco’s first subsidiary, Laboratorios Cinfa, has become a recognised leader in the Spanish pharmaceutical market. As part of the internationalization strategy, the company also serves in currently over 50 countries and is further expanding.
For more information, please visit: http://www.cinfabiotech.com
For press enquiries:
MC Services AG
Julia von Hummel, Kaja Skorka, Shaun Brown
Phone: +49 89 210 228-0
Email: cinfabiotech[at]mc-services.eu
